JP2016117767A5 - - Google Patents

Download PDF

Info

Publication number
JP2016117767A5
JP2016117767A5 JP2016058474A JP2016058474A JP2016117767A5 JP 2016117767 A5 JP2016117767 A5 JP 2016117767A5 JP 2016058474 A JP2016058474 A JP 2016058474A JP 2016058474 A JP2016058474 A JP 2016058474A JP 2016117767 A5 JP2016117767 A5 JP 2016117767A5
Authority
JP
Japan
Prior art keywords
composition
hours
release layer
methylphenidate
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016058474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016117767A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016117767A publication Critical patent/JP2016117767A/ja
Publication of JP2016117767A5 publication Critical patent/JP2016117767A5/ja
Withdrawn legal-status Critical Current

Links

JP2016058474A 2011-03-23 2016-03-23 注意欠陥障害の処置のための方法および組成物 Withdrawn JP2016117767A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161466684P 2011-03-23 2011-03-23
US61/466,684 2011-03-23
US201161561763P 2011-11-18 2011-11-18
US61/561,763 2011-11-18
US201261591129P 2012-01-26 2012-01-26
US61/591,129 2012-01-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014501292A Division JP6043785B2 (ja) 2011-03-23 2012-03-23 注意欠陥障害の処置のための方法および組成物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017091305A Division JP6325148B2 (ja) 2011-03-23 2017-05-01 注意欠陥障害の処置のための方法および組成物
JP2018179001A Division JP2018197276A (ja) 2011-03-23 2018-09-25 注意欠陥障害の処置のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2016117767A JP2016117767A (ja) 2016-06-30
JP2016117767A5 true JP2016117767A5 (https=) 2017-06-15

Family

ID=46879766

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2014501292A Active JP6043785B2 (ja) 2011-03-23 2012-03-23 注意欠陥障害の処置のための方法および組成物
JP2016058474A Withdrawn JP2016117767A (ja) 2011-03-23 2016-03-23 注意欠陥障害の処置のための方法および組成物
JP2017091305A Active JP6325148B2 (ja) 2011-03-23 2017-05-01 注意欠陥障害の処置のための方法および組成物
JP2018179001A Withdrawn JP2018197276A (ja) 2011-03-23 2018-09-25 注意欠陥障害の処置のための方法および組成物
JP2020035076A Withdrawn JP2020079322A (ja) 2011-03-23 2020-03-02 注意欠陥障害の処置のための方法および組成物
JP2022030878A Withdrawn JP2022066315A (ja) 2011-03-23 2022-03-01 注意欠陥障害の処置のための方法および組成物
JP2023223409A Withdrawn JP2024019726A (ja) 2011-03-23 2023-12-28 注意欠陥障害の処置のための方法および組成物
JP2026006778A Pending JP2026063249A (ja) 2011-03-23 2026-01-19 注意欠陥障害の処置のための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014501292A Active JP6043785B2 (ja) 2011-03-23 2012-03-23 注意欠陥障害の処置のための方法および組成物

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017091305A Active JP6325148B2 (ja) 2011-03-23 2017-05-01 注意欠陥障害の処置のための方法および組成物
JP2018179001A Withdrawn JP2018197276A (ja) 2011-03-23 2018-09-25 注意欠陥障害の処置のための方法および組成物
JP2020035076A Withdrawn JP2020079322A (ja) 2011-03-23 2020-03-02 注意欠陥障害の処置のための方法および組成物
JP2022030878A Withdrawn JP2022066315A (ja) 2011-03-23 2022-03-01 注意欠陥障害の処置のための方法および組成物
JP2023223409A Withdrawn JP2024019726A (ja) 2011-03-23 2023-12-28 注意欠陥障害の処置のための方法および組成物
JP2026006778A Pending JP2026063249A (ja) 2011-03-23 2026-01-19 注意欠陥障害の処置のための方法および組成物

Country Status (15)

Country Link
US (1) US9028868B2 (https=)
EP (4) EP2688557B1 (https=)
JP (8) JP6043785B2 (https=)
KR (2) KR101834033B1 (https=)
CN (2) CN103608004A (https=)
AU (3) AU2012230733B2 (https=)
BR (1) BR112013024401B1 (https=)
CA (1) CA2830788C (https=)
DK (3) DK3272342T3 (https=)
ES (3) ES2644942T3 (https=)
MX (4) MX2021000431A (https=)
PT (3) PT2688557T (https=)
SG (2) SG193587A1 (https=)
WO (1) WO2012129551A1 (https=)
ZA (1) ZA201307649B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905652B2 (en) * 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) * 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) * 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
GB201319791D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
SG11201708393UA (en) * 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
PL3324948T3 (pl) * 2015-07-17 2023-06-26 BE Pharbel Manufacturing Wielowarstwowe mikrocząstki uwalniające związek farmaceutycznie aktywny w płynnej postaci dawkowania
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
WO2017027778A1 (en) * 2015-08-13 2017-02-16 Temple University-Of The Commonwealth System Of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
US12274794B2 (en) * 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US9931303B1 (en) 2017-02-06 2018-04-03 Alcobra Ltd. Abuse deterrent formulations of amphetamine
US20180256515A1 (en) * 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
PT3616696T (pt) * 2017-04-28 2025-04-03 Astellas Pharma Inc Composição farmacêutica administrável oralmente contendo enzalutamida
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
ES2938609T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
CN108653243B (zh) * 2018-03-30 2019-03-22 江苏南农高科动物药业有限公司 一种缓释替米考星微囊粉的制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
WO2020154580A1 (en) * 2019-01-25 2020-07-30 Ironshore Pharmaceuticals & Development, Inc. Methylphenidate compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DK0384646T3 (da) 1989-02-16 1993-07-12 British Tech Group Dispenseringsindretning
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
JP2916978B2 (ja) 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
MX9805870A (https=) 1996-01-22 1999-01-31
JP2000504008A (ja) 1996-02-02 2000-04-04 メデバ・ユアラプ・リミテッド Ｄ―トレオ―（ｒ，ｒ）―メチルフェニデートの調製およびエピメリゼーションによる不要エナンチオマーリサイクルの方法
ES2173422T3 (es) 1996-03-08 2002-10-16 Medeva Europ Ltd Disociacion de treo-metilfenidato.
GB9606417D0 (en) 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
ES2262174T3 (es) 1996-09-30 2006-11-16 Alza Corporation Forma de dosificacion y procedimiento de administracion de medicamentos.
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2264173T3 (es) 1996-11-25 2006-12-16 Alza Corporation Forma de dosificacion para suministrar una dosis creciente.
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
CZ206299A3 (cs) 1996-12-13 1999-09-15 Medeva Europe Limited Způsob přípravy enantiomerně obohaceného THREO-metalfenidátu
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US6898455B2 (en) 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6520921B1 (en) 2000-06-20 2003-02-18 Eastman Kodak Company Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US6726624B2 (en) 2002-03-06 2004-04-27 The Mclean Hospital Corporation Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7348028B2 (en) 2002-09-09 2008-03-25 Kenneth Stephen Albert Chronotherapeutic diltiazem formulations and the administration thereof
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
CA2514879C (en) 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
MXPA05012850A (es) 2003-05-29 2006-05-17 New River Pharmaceuticals Inc Compuestos de anfetamina resistentes al abuso.
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
ES2299995T3 (es) 2004-01-29 2008-06-01 Pfizer, Inc. Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4.
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
WO2006081518A2 (en) * 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
PL2457563T3 (pl) * 2006-05-09 2017-09-29 Mallinckrodt Llc Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
JP5052602B2 (ja) * 2006-05-12 2012-10-17 シャイア エルエルシー 制御用量薬物送達システム
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
CN1985810A (zh) * 2006-07-28 2007-06-27 中国人民解放军第二军医大学 盐酸哌甲酯缓控释胶囊及其制备方法
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
US8642083B2 (en) 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
EP2079456B1 (en) 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
KR101616246B1 (ko) * 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
CA2627198A1 (en) 2008-03-27 2009-09-27 Pharmascience Inc. Methylphenidate extended release therapeutic drug delivery system
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse

Similar Documents

Publication Publication Date Title
JP2016117767A5 (https=)
JP2014508812A5 (https=)
EP2363117B1 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
KR101090719B1 (ko) 프로프라놀롤의 시간조절-지속 방출성 다중-과립형 투여 형태
US8133506B2 (en) Drug delivery systems comprising weakly basic drugs and organic acids
US20060204575A1 (en) Amphetamine formulations
JP6359022B2 (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
US8865213B2 (en) Modified release pharmaceutical compositions
JP6759426B2 (ja) Ｃｎｓ化合物の安定化製剤
US10213389B2 (en) Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
AU2015349896B2 (en) Pharmaceutical bead formulations comprising dimethyl fumarate
US20160228388A1 (en) Methods of administering amantadine compositions
JP2019123736A (ja) ビロキサジンの緩和放出製剤
JP2665858B2 (ja) 持効性塩酸オキシブチニン製剤
JP2013523757A (ja) マジンドールの製剤
JP2014504633A (ja) 経口投与用放出制御医薬組成物
CN102764243B (zh) 一种阿司匹林脉冲释放微丸和其制剂及其制备方法
US20170333350A1 (en) Pharmaceutical Composition Comprising Dabigatran Etexilate, And Preparation Method, Solid Preparation And Use Thereof
WO2020115709A1 (en) Modified release pharmaceutical composition
AU2013204408B2 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
CN1712002A (zh) 盐酸罗匹尼罗渗透泵型控释制剂及其制备方法
HK1161695A (en) Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids